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The success of implantable devices relies heavily on their interaction with the host cells facilitating the 
osteointegration process.  However, with so many new surface modifications, with subtly varying design parameters, in 
vitro assays can, with proper interpretation, provide valuable information for understanding cellular behaviour.  This 
review brings together pertinent in vitro experimental protocols available to researchers and discusses them in relation 
to the development of the osteoblast phenotype during bone repair.  Consideration is also paid to the influence of 
endothelial and macrophage cells that can substantially change osteogenic cell activity and thus can provide added 
value for predicting the osseointegration potential in vivo.  Due to the diverse and heterogeneous nature of cell types 
available for culture use, this review concludes there is no “gold standard” series of assays.  Rather we present guidance 
in the experimental design of in vitro assays to better identify those surfaces with promising osteogenic potential. 
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Titanium implants are already widely used in orthopaedics and dentistry, yet intensive research continues with the aim 
of modifying and functionalising implant surfaces to invoke a stronger bone response and to meet current clinical 
challenges around improving longevity, decreasing morbidity, widening access and clinical application.  A very large 
number of surface modifications have been studied and the potential for new designs appears to be limitless as new 
technology grows.  This review provides guidance for in vitro assays available to test these technologies, providing a 





Titanium implantable devices have provided a successful treatment option in many areas of reconstructive 
orthopaedic and cranioplasty medicine and dentistry.  However, despite these clinical successes, many challenges for 
their use remain.  These include increasing the longevity of the implant and widening their use to age-related conditions 
where bone quality is reduced, such osteoporosis and type 2 diabetes mellitus1.  For these reasons, research efforts 
look to develop novel implant surfaces that can rapidly and effectively integrate within host bone tissue.  However, in 
researching these metals a plethora of surface modifications have been developed, all demonstrating an ability to 
modulate the activity of skeletal stromal cells to proliferate and then differentiate into bone synthesising osteoblasts. 
In vitro assessments of osteogenic activity predominantly investigate how surface modification influences the 
biological responses of the skeletal stromal cells.  Of these assays, cell survival and an ability to form attachments with 
serum proteins coating the implant surface are key questions.  These will inform data arising from subsequent assays 
that indicate if the surfaces promote cell proliferation and cell differentiation towards an osteoblast phenotype capable 
of synthesising a mineralised matrix.  However, the literature can produce contradictory studies, attributable to the 
numerous and varying in vitro methods of analyses used by researchers, with no “gold standard” for investigation 
definable.  The problem is also that in vitro assays are prone to artefact and misinterpretation unless the underpinning 
biological basis for the assay, aligning to development of the osteoblast phenotype during the bone healing process, are 
fully appreciated.  
This review aims to provide an evaluation of appropriate in vitro assays currently used for assessing the 
osseointegration process.  In recognising that angiogenesis and macrophage function are also drivers for successful 
osseointegration, this review will additionally look at robust assays to assess the behaviour of these cells to implant 
surfaces.  Overall, we aim to highlight some fundamental considerations to allow researchers to make more informed 
choices when designing experiments, interpreting the resulting data and evaluating data against that in the literature. 
 
Bone biology during osseointegration 
When we consider that osseointegration involves the production of new bone tissue that interfaces with an 
implant surface it is unsurprising that this process is not dissimilar to the process that occurs during fracture repair of 
bone.  However, and more importantly, recognising the sequence of biological events associated with bone healing is 
vital for understanding methodological principles of in vitro assays used to evaluate osteogenic potential of an implant 
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surface and critical evaluation of results arising.  The process of osseointegration can be briefly divided into four 
overlapping stages of: haematoma formation, inflammatory phase, reparative process and remodelling (Figure 1). 
Before implant placement, the relevant area of bone is drilled to a size that reduces any potential micromotion of the 
implant to a minimum and enhancing successful bone healing around the implant2. The resultant process of bone 
healing is described in many other reviews3,4,5 and thus key cells and signalling factors are summarised in Figure 1.  
Depending on the surface properties and characteristics of the implant, a variety of proteins from the blood and 
surrounding interstitial tissue fluid are adsorbed onto the implant surfaces, that modulate binding of skeletal progenitor 
cells and pre-osteoblasts, through interactions with cell surface integrins6.  Importantly, is the development of a 
haematoma which provides a stable framework for a wound healing site that facilitates a route of cell migration to the 
implant surface7,8.   
Other important cells are macrophages that are proposed to serve numerous roles including phagocytosis of 
foreign particles, bone debris and microbial contaminants9,10,11.  It is therefore unsurprisingly acknowledged that an 
“appropriate” initial inflammatory response is fundamental for initiating and propagating the subsequent reparative 
process leading to the deposition of woven bone3,4,5.  The local environment also contains a myriad of growth factors 
(Figure 1) that initiate the process of cell differentiation and tissue formation, during which angiogenesis is a pre-
requisite.  Differentiating osteoblasts begin to secrete the osteoid matrix, which is rich in type I collagen (COL1) but also 
contains matrix proteins, such as matrix extracellular phosphoglycoprotein (MEPE) and osteopontin (OPN), that inhibit 
premature mineral deposition12,13.  Once the structural framework of the collagen matrix is laid down these inhibitors 
of mineralisation are removed by specific matrix metalloproteinases and the osteoblasts synthesise a new pool of non-
collagenous proteins that guide and regulate the interfibrillar growth of hydroxyapatite crystals12,13.  
 
In vitro assessment for the assessment of osteoblast differentiation 
It is recognised that in vivo assessments will provide the necessary biological evaluation of medicinal products, 
conforming to ISO 10993 (comprehensively reviewed by Von Wilmosky et al14).  However, a review of the literature 
clearly tells us that there is a great reliance on in vitro assessments, which are utilised to provide high throughput 
quantifiable data for measuring cell responses and understanding mechanistic signalling in a controlled culture 
environment; addressing the research question “is a surface capable of directly inducing an osseogenic response in bone 
marrow stromal cells (BMSCs).”  Table 1 highlights the advantages of in vitro studies in providing an easier route to 
identifying those surface preparations that can provide good positive evidence for promoting osseointegration.  
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Nonetheless, the largest area for diversity in the research findings for in vitro studies is primarily linked to the starting 
population of cells used, which in turn can influence the results obtained for the fairly commonplace assays employed 
to quantify cell attachment, proliferation and osteoblast differentiation.  An additional caveat to considering in vitro 
data is that bone formation in vivo involves paracrine regulation from other cells, including the various immune cells, 
osteoclasts and endothelial cells.  Consequently, there is no guarantee that these observations translate to the in vivo 
scenario.  This conclusion has been demonstrated in a multi-centre review which identified that there was no overall 
significant correlation between in vitro and in vivo outcomes in the assessment of biomaterials, and that drawing 
definitive conclusions between studies is thus incredibly difficult, which can be attributed to a number of credible 
compounding factors relevant to the assay protocol influencing result outcome15.  This stated, in vitro and in vivo data, 
if performed and reviewed carefully to consider limitations and caveats, can be complementary and if demonstrating 
contradictory results, can be informative for the design of further studies to address the pertinent questions arising.   
 
Considerations for cell source used in assays  
A wide variety of cell types, all capable of differentiating into osteoblasts, are available for in vitro study.  Table 
2 highlights some of the more common cell types used to assess osteogenic potential and their advantages and 
disadvantages.  The key information many studies aim to obtain is to provide a measure of osteogenic potency and 
efficacy.  Potency can be defined as the ability to bring about a particular result, whilst efficacy relates to the measure 
of the intensity of the potent effect observed16.  If studies are well controlled and starting conditions are standardised, 
the measure of potency and efficacy within a study is possible.  However, efficacy is harder to compare when wishing 
to evaluate separate studies.  This is because the various cell lines available for use vary greatly with respect to their 
phenotypic differentiation status, which will impact on cell proliferation and time required to achieve a fully 
differentiated osteoblast17,18.   
 
Cells derived from primary tissue source 
Many studies use primary sources to derive BMSCs since they are considered to represent more closely the 
cells interacting with an implant surface in vivo.  However, nomenclature for these cells provides one of the largest areas 
for ambiguities and in 2006, a working group of the International Society for Cellular Therapy (ISCT) recommended a 
new designation of multipotent mesenchymal stromal cells19 rather than mesenchymal stem cells (MSC).  This is 
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because, and in the absence of definitive cell markers, a cell’s “stemness” is difficult to evaluate in post-natal populations 
that are also likely to contain tissue specific progenitor cells and non-stem cells20.  This is supported by recent data to 
suggest that stromal cell populations isolated from bone marrow and then culture expanded contain variable 
concentrations of multi-potent cells; along with cells that are bi-potent for either osteogenic-adipogenic, osteogenic-
chondrogenic, adipogenic-chondrogenic differentiation; uni-potent cells that represent lineage restrictive progenitor 
cells; and nulli-potent cells that fail to differentiate down one of the classical lineages, but are proposed to represent an 
immuno-supportive subtype17,18.  Consequently, a better recognised description for primary cells used in in vitro assay 
is to refer to these cells as stromal cells relevant to the tissue of primary origin (for example bone marrow stromal cells 
or calvarial stromal cells).   
As a further consideration, variation in the proportions of these populations will influence the paracrine and 
autocrine signalling environment, which will in turn influence the quantitative data arising from in vitro assays.  The 
profile of these stromal cells can also vary with increasing passage, where the more highly proliferative multi-potent 
cells assume dominance within the culture, although further continued passaging leads to deterioration of their 
reparative ability21.  Other studies have suggested that osteogenic potential is lost through in vitro culture whereas 
adipogenic differentiation potential remains22.  Moreover, when using human cells the heterogeneric profile of BMSCs 
is subject to donor variability which can partially be attributed to age, race and gender, as well as systemic condition 
such as osteoporosis and type 2 diabetes, that can impair their regenerative capacity.  Commercial sources for human 
BMSCs are available but patient information is limited and batch-to batch heterogeneity with respect to cell populations 
and manufacturing methods is a confounding factor23.  A further consideration is that within the bone marrow cavity 
these skeletal progenitor cells exist in either a perivascular or periosteal location and the two sets of cells differ markedly 
in the function they provide to bone remodelling and bone repair24.  Isolation of bone marrow may take variable 
proportion of perivascular and periosteal associated cells which can differ with respect to their proliferative and 
differentiation potential.   
Sourcing primary skeletal stromal cells from rodent animals can, therefore, appear to provide several 
advantages in that age and systemic status of the donor animal can be controlled.  However, inherent differences exist 
in the balance of immunological cells between human and rat or mice derived cells  and considering the role of these 
cells in regulating bone turnover, it is not a surprise that differences exist between rodent and human bone marrow 
derived cells in their osteogenic potential25.  Indeed, it is noted that the differentiation of rat BMSCs into mature 
osteoblasts occurs between 7 and 14 days earlier compared with BMSCs from human origin, which can require up to 42 
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days culture to produce a dense mineralised matrix26,27.  Further, studies have indicated that mouse BMSCs isolated via 
plastic adherence contain higher levels of haemopoietic cells compared to human derived populations isolated via the 
same protocol28,29.  Numerous studies have also compared the osteogenic potential of stromal cells acquired from 
mandibular, where cells embryonically derive from the neural crest origin, and limb sites, where cells derive from the 
mesoderm.  An overwhelming consensus has identified a greater osteogenic capacity for mandibular-derived stromal 
cells, compared to cells acquired from long bones, in species such as rats30 and pigs31 and the iliac crests of humans32. 
 
Osteoblast cell lines 
Several commercial cell lines derived from osteosarcoma or spontaneously immortalised cells are available.  
These cells can offer advantages for providing an unlimited number of cells and represent a more homogenous cell 
population.  However, one key consideration when using immortalised osteoblast cell lines is the numerous phenotypic 
differences compared to primary cell lines or osteoblasts. A comprehensive review by Czekanska et al33 details how 
different immortalised and primary cell lines, cultured in identical media and conditions leads to differences in alkaline 
phosphatase (ALP) activity and mineral deposition within the synthesised matrix.  This in turn, correlates with known 
variations in proliferation and osteoblastic marker expression.  Significantly, studies have identified that SaOS-2, derived 
from a human osteosarcoma cell line, represents a mature osteoblast phenotype and thus do not mirror the whole 
range of osteoblast differentiation.  MG-63 cells and SaOs-2, are reported to be p53 deficient34.  This arrests cells in the 
pre-osteoblast state, resulting in rapid cell division without contact inhibition, which is associated with an inability to 
express osteocalcin (OCN)35, and associated inconsistencies in mineral deposition36,37,38.  MC3T3-E1, a clonal cell line 
derived from new-born mouse calvaria is a popular animal cell line, although immunological issues of interspecies 
difference described above are to be considered.  As clonal cell lines MC3T3-E1 show good homogeneity, although cells 
at high passage show decreased proliferation, due to inconstancies in cell cycling and evidence of replicative senescence, 
which influences post-proliferative stages associated with deposition of a mineralised matrix33,36.  
 
Seeding density 
One recurring observation in reviewing the literature for in vitro assay protocols, is the variation in the seeding 
density of cells onto the implant substrate. Human and rodent derived cells are frequently seeded at densities as low as 
5,000 cells/cm2, to as high as 40,000 cells/cm2, with rodent stromal cells generally seeded at the higher densities26,37,37,39.  
8 
 
Seeding densities of osteoblastic cell lines range from between 10,000 cells/cm2 up to 85,000/cm2   40,41,42.  A key 
consideration in deciding an appropriate seeding density  relates to the widely accepted consensus of the reciprocal 
relationship between cell proliferation and differentiation; cells typically undergo an initial active proliferative phase 
which is then required to down-regulate prior to cell differentiation and osteoid production43,44.  This knowledge thus 
explains why BMSCs at a higher density in culture undergo osteogenic differentiation more readily than cells at a lower 
density45.  However, it is also noted that higher seeding densities of BMSCs can result in a bias towards adipogenic 
differentiation as opposed to osteogenic46,47.  Cell seeding density, reported for those cells in contact with the implant 
substrate, is therefore better optimised on an individual basis to ensure appropriate conditions that ultimately permit 
the researcher to confidently identify surface influences, initially examining active cell proliferation which is then 
observed to plateau prior to observation of differentiation markers towards an osteoblastic lineage.  
 
Cell attachment and morphology 
It is now well established that cell attachment to a matrix is necessary to promote cell survival and prevent 
anoikis (programmed cell death of anchorage-dependent cells following detachment from the surrounding extracellular 
matrix)48,49, as well as dictating a cell’s ability to proliferate and differentiate towards the osteoblast lineage.  When 
exposed to human plasma, 48% of proteins adsorbing onto the titanium surfaces have been implicated in facilitating 
cellular adhesion50.  Formation of focal adhesion points between v3 and  51 integrins on SaOS-2 osteoblast-like cells 
and RGD sequences within adherent proteins fibronectin or vitronectin coated surfaces have been shown to enhance 
cell proliferation compared to uncoated surfaces51.  In addition, interactions of 5 integrins with RGD peptide motifs has 
been associated with an upregulation of osteogenic differentiation of progenitor cells52,53.  However, for cells grown on 
plastic, pure titanium and calcium phosphate surfaces, differences in the profile of proteins adsorbed to the surface can 
lead to changes in integrin expression by cells54.  Surface roughness can also alter the profile of proteins absorbed, with 
rougher surfaces (Ra of 183.2 nm) adsorbing higher quantities of fibronectin and albumin compared to smooth 
machined surfaces (Ra of 53.5nm), which has in part been attributable to enhanced cell binding potential55.   
The formation of focal adhesion points can direct cell morphology.  Cells with a branched cell morphology and 
a highly organised cytoskeleton, with defined focal adhesion points, correlate well with increased osteogenic potential56.   
These changes in cell morphology and hence changes in the cytoskeletal proteins lead to the altered expression of 
several osteoblast genes, regulated via extracellular regulated kinase (ERK), focal adhesion kinase (FAK) and mitogen-
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activated protein kinase (MAPK) signalling cascades57,58.  These studies, and many others also exemplify how the steric 
arrangement of cell surface focal adhesion points are important for directing cellular behaviour and this has formed a 
fundamental understanding for how surface topography can dictate cell behaviour (reviewed by Cutis and Wilkinson59).   
 
Media supplementation 
A review of protocols used in the literature, indicates that around a third of studies chose to include osteogenic 
inducing factors within the culture media.  There are many studies that do not supplement media with osteogenic 
induction factors, providing plentiful evidence that certain surface topographies are sufficiently capable of inducing 
osteogenic responses of BMSCs from humans and rodents60-63.  For those that include osteogenic factors, the culture 
media is invariably supplemented with: dexamethasone, which up-regulates Runt-related transcription factor 2 (Runx2) 
expression; ascorbic acid, which stimulates collagen fibril synthesis; and β-glycerophosphate, which provides a source 
of phosphate (reviewed by Langenbach and Handschel64).  However, one research article of note is that of Sisti et al65, 
where human BMSCs were cultured on various surfaces in both the absence and presence of 10nM dexamethasone.  
Interestingly, no differences in mRNA expression of ALP and OPN were observed for cells cultured on different surfaces 
in osteogenic-inducing medium, but significant differences for these markers were identified for cells cultured on the 
same surfaces in basal medium.  Inclusion of osteogenic factors may therefore mask small to moderate osteogenic 
effects due to the surface, which are difficult to observe against the potent osteogenic influence of factors such as 
dexamethasone.  Inappropriate supplementation can also produce false positive results.  For example, treatment of 
cells, nominally incapable of osteogenic differentiation with ≥2 mM β-glycerophosphate can result in dystrophic 
mineralisation that stains positive for Alizarin Red or von Kossa60,64.  Further it should be remembered that commercial 
media preparation may already contain ascorbic acid and endogenous phosphate, reiterating the question is it 
necessary to add osteogenic supplementation?  
 
Measuring early markers for osteoblast differentiation in vitro 
Osteoblast differentiation is guided by a complex signalling pathway that requires the synthesis of transcription 
factors, growth factors, growth factor receptors and extracellular proteins that serve to regulate cell signalling and 
regulate (both through inhibition and promotion) mineral deposition.  These all represent useful biomarkers for 
measuring osteogenic differentiation (Figure 2), recapitulating in vivo events that are measurable in differentiating cells 
within 2D culture environments66.  Analyses can be via measurement of gene expression or the synthesis of a protein.  
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What is often overlooked, however, is that the expression of many of the osteogenic genes is temporal; gene expression 
switches on at a specific maturational stage and is then required to be switched off again to allow differentiation to 
proceed (Figure 2).  Analysis, therefore, only represents a “snapshot” of the cellular differentiation status at a specific 
moment in time.  Consequently, it can be unclear whether analysis for the expression of a specific gene is measuring an 
increasing expression, at the peak of expression or when the gene is being regulated to switch off.    
An ideal example to demonstrate this limitation in data interpretation is in the measurement of Runx2.  Runx2 
is widely regarded as a prerequisite transcription factor required for differentiation towards an osteoblastic 
phenotype67,68.  Runx2 expression is induced by DLX5, regarded as the master transcriptional regulator for osteogenesis 
and in turn Runx2 has been linked with promoting the expression of many of the bone matrix proteins such as COL1, 
OPN, bone sialoprotein (BSP) and OCN.  However, studies have indicated that overexpression of Runx2 in differentiating 
osteoblasts severely reduces OCN expression by inhibiting osteoblast maturation67,68.  Consequently, Runx2 has been 
proposed roles in committing multipotent cells to pre-osteoblasts, but requires to be down-regulated in order to permit 
terminal differentiation to a mature osteoblast phenotype69,70.  Whilst levels of expression are variable depending upon 
a multitude of factors including cell type, initial seeding density, culture conditions and cell-material interactions, a 
limitation for many analyses is the difficulty in identifying the point in which Runx2 expression peaks before reducing 
expression to permit terminal differentiation, hence potentiating false results.  Through monitoring of Runx2 expression 
at multiple daily time points it is possible to provide an indication for how rapidly an implant surface may induce 
osteoblast differentiation. 
The use of Runx2 as a marker for osteoblast differentiation comes with additional forewarnings; the role of 
Runx2 as a master gene for indicating commitment of stromal cells to the osteoblast lineage is controversial.  Whilst 
Runx2 expression has been indicated to inhibit adipogenic differentiation, its expression has been associated with 
chondrogenesis71,72.  Furthermore, it is reported that multipotent cells of human origin constitutively express Runx273.  
Indeed, it has been suggested that in vitro osteogenic differentiation of BMSCs with dexamethasone is more regulated 
by phosphorylation of the Runx2 protein, and not as a consequence of an increase in Runx2 expression, which is thought 
to remain the same74.  More specific to osteogenic differentiation is the expression for the gene encoding for osterix 





Measuring markers for mid to late osteogenic differentiation 
In vitro studies also consider the expression of markers considered to the associated with either the 
development of the immature or mature osteoblast phenotype.  One such marker is ALP, which is measured either at 
gene level or through colorimetric assays.  ALP is an enzyme that plays a role in the hydrolysis and liberation of 
phosphate groups on proteins and in the hydrolysis of inhibitory pyrophosphates, providing a free source of phosphate 
ions for incorporation into the hydroxyapatite crystal lattice76,77.  These functions of ALP mean that the enzyme is 
expressed in high levels in immature osteoblasts and is widely used as an indicator of early osteogenic 
differentiation78,79,80.  However, it is also important to consider that ALP isoforms are also present in multipotents81 and 
pluripotent cells82 and is down regulated when cells enter the M phase during the cell cycle83.   
Another regular marker for osteogenic differentiation is OPN (also known as secreted phosphoprotein, SPP1).  
Within the bone healing process OPN is synthesised by pre-osteoblasts and immature osteoblasts, but it is also highly 
synthesised by macrophages9.  OPN binds to newly exposed bone surfaces to becomes incorporated in cement lines 
delineating new and old bone surfaces9.  It binds to debris bone pieces and serves as an opsonin for clearance by 
macrophages9.  Whilst OPN appears to be one of the earliest secreted proteins, it has been identified as a negative 
regulator for the proliferation and differentiation of MC3T3-E1 cells, where its overexpression has been shown to inhibit 
responsiveness to bone morphogenic protein-2 (BMP-2)84.  OPN has been shown to bind to specific faces of the 
hydroxyapatite crystal where it inhibits mineral crystal growth85,86.  Thus, it is essential to demonstrate down-regulation 
of OPN to demonstrate full differentiation to a mature osteoblast phenotype.   
Considering that osteogenic markers may not be continually expressed at high levels for the duration of the 
osteogenic differentiation, better studies provide analysis for multiple osteogenic markers to identify early, mid and 
late stage of differentiation, at multiple time points in order to help maximise the possibility of identifying the peak 
expression.  Additional markers of differentiation towards osteoblasts that can additionally be assessed to include, but 
not limited to, COL1, BSP and OCN33.  However, possibly the clearest marker for the formation of a mature osteoblast is 
its ability to deposit a mineralised matrix which can be measured using protocols for staining of calcium by Alizarin red 
and its release following subsequent dissolution of bone mineral nodules with acetic acid87.  The deposition of a 
biological apatite, and not monophasic forms of calcium phosphate should ideally be confirmed, which is possible using 




In vitro assessment of macrophage activity 
Macrophages play important roles in the clearance of cell debris, bacteria and other small particulates such as 
small bone debris at the implant site9.  They also play important roles in regulating osteoblast activity via the expression 
of pro- and anti-inflammatory cytokines89.  However, when assessing the osseointegration potential of a titanium 
surface, neglecting the role of the immune cells is a frequent omission to many of the published studies.  Macrophages 
are now recognised to broadly exist in two distinct polarized subsets; M1 which is ascribed roles in destroying pathogens 
and propagation of the pro-inflammatory response, and M2 which is attributed roles in tissue repair, angiogenesis and 
re-establishment of homeostasis89,90 (Figure 3).  A transition from the M1 phenotype to the M2 phenotype is seen as 
prerequisite for good bone healing89,90, where prolonged presence of M1 macrophages has potential to extend 
inflammation and thus delay reparative responses89,90.  The polarisation to M1 or M2 can readily be distinguished.  M1 
characteristically release pro-inflammatory cytokines interleukin 1β (IL-1β), IL-6, IL-12, IL-23, TNF-α along with iNOS and 
carry cell surface markers CD86 and CCR789,90.  M2 polarised macrophages are characterised by cell surface markers 
CD163 and CD206 and the production of anti-inflammatory factors such as IL-10, transforming growth factor-β  (TGF-
β), BMP-2, vascular endothelial growth factor (VEGF) and Arginase-189,90, some of which are notable for their role in 
promoting osteoblast differentiation and bone healing.  In vitro studies investigating macrophage polarisation may use 
monocytic cells isolated from blood91 or bone marrow92 which offer the advantage that they derive from a human 
source, but the isolated cells will be heterogeneous with respect to the proportions of M1 and M2 phenotypes, amongst 
other monocytic cells.  Studies have also used commercial transformed lines such as the well established RAW 264.7 
cells or the human derived THP-1 monocytic cells, which may be easier to culture, but come with the cautions of using 
immortalised cell lines.     
The important role macrophage polarization plays in influencing the osseointegration process and osteoblast 
function has been used to explain differences witnessed in the osteogenic potential of titanium surfaces seen in in vitro 
and in vivo studies.  Using a range of established in vitro osteogenic assays, a series of publications have studied how 
the width of nanotubes fabricated onto titanium surfaces influences the osteogenic process; indicating that those 
etched with wider nano-tubes demonstrated a greater osteogenic response91,92.  However, in vivo studies using the 
same etching patterns suggested that those surfaces etched with the smaller diameter nano-tubes promoted bone 
formation, which was associated with less inflammation91,92,93.  This dichotomy was addressed following analysis of 
recovered conditioned media from macrophage cells cultured on the titanium surfaces, which suggested that those 
surfaces promoting M2 polarisation also promoted osteoblast differentiation of BMSCs92,93 and concurs with reports 
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that M2s secrete BMP-2 and TGF-β94,95.  Additionally, M2 polarisation has also been shown to promote in vitro 
angiogenesis of  human umbilical vein endothelial cells (HUVECs), attributable to VEGF secretion96.  
Studies have additionally reported that hydrophobic titanium surfaces result in a diminution of M2 phenotype 
as judged by increases in pro-inflammatory gene expression97,98 and it has been hypothesised that this surface feature 
has the greatest effect in determining macrophage fate99.  The ability of hydrophilic and rough surfaces to promote M2 
polarisation has been hypothesised to be attributed to enhanced protein adsorption and maintenance of protein 
conformation, thereby providing attachment for the cells.  Attachment of macrophages to a protein adsorbed surface 
allows for cell spreading and induces changes in cell shape facilitated by changes in F-actin content and cell surface 
adhesion proteins100.  The importance of signalling via the actin cytoskeleton has been demonstrated using cytochalasin 
B, which binds to the ends of extending actin filaments and inhibits cytoskeletal-dependant shape changes101.  High 
concentrations of this inhibitor produced rounded macrophages with reduced BMP-2 secretion.  Additionally, the 
cytoskeleton influences cell contact and adhesion sites, where the contribution of β1 and to a lesser extent β3 integrins 
in the process of M2 polarisation has been indicated using blocking antibodies102.      
 
Assessment of angiogenesis as part of the osseointegration process 
The requirement for new blood vessel formation in promoting successful bone repair and osseointegration of 
an implant is well acknowledged.  Signalling factors produced by endothelial cells bring reparative skeletal stromal cells 
to the wound site103,104 and regulate maturation into osteoblasts105.  For the few studies investigating in vitro responses 
of endothelial cells to titanium surfaces, HUVECs are commonly used as a highly characterised and commercially 
available cell line.  Simple protocol procedures have been successfully employed to isolate HUVECs from an umbilical 
tissue source106,107,108 and buffy coats from blood109.  These populations are inevitably heterogeneous, containing 
variable numbers of endothelial precursor cells, which further divide into colony-forming cells or late outgrowth cells, 
which differ considerably with respect to their morphology and proliferative potential110.   
In vivo, angiogenesis involves either endothelial sprouting or intussusceptive angiogenesis (forming new 
vessels through the splitting of one vessel) and smooth muscle cells and pericytes line the endothelial vessels110.  In vitro 
angiogenic assays do not usually consider these additional mural cells, and thus established assay protocols are limited 
to investigating early angiogenic responses.  This can include assessment of cell proliferation by either direct cell counts 
107, or via assays that correlate with cell metabolic reductase activity such as the MTT assay106,110 or the Alamar blue 
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assay106.  The influence of surfaces on cell survival can also be readily assessed using apoptosis assays or the detection 
of other pro-apoptosis factors such as caspase-3, Bax and Fas ligand111 or the secretion of angiopoietin-1 (Ang-1), VEGF, 
platelet derive growth factor (PDGF) and fibroblast growth factor-2 (FGF-2)112,113,114; the latter grouping representing 
factors that also positively promote the proliferation and differentiation of progenitor cells to osteoblasts103,104.  
Although limited in number, studies have suggested that greater numbers of endothelial cells adhere to smooth surfaces 
compared to rough surfaces109.  Conversely, functionalisation of titanium with TiO2 nanowires has been shown to 
enhance secretion of VEGF and increase mRNA expression of VEGF, FGF-2, PDGF and fibroblast growth factor receptor 
2 (FGFR2) in HUVECs when compared to un-functionalised surfaces108.   
Monitoring of cell migration using wound scratch assay on titanium surfaces has been shown to be more 
problematic, primarily due to difficulties in viewing the cells on an opaque surface which necessitates fluorescence 
staining of cells in order to assess wound closure at fixed time points106,108.  Likewise, in vitro assessments for the ability 
of titanium surfaces to support tubular network formation and terminal endothelial differentiation have proved difficult.  
This is because in vitro tubulogenesis assays require endothelial cells to be incorporated within or on top of an 
extracellular matrix gels and coating surfaces with these gels usually abrogates the assessment of geometric surface 
modification or surface functionalisation.   
 
Concluding remarks 
Currently, there is no consensus for identifying a standardised series of in vitro assays able to quantitatively 
assess the impact of an implant modification for promotion of the bone healing process.  This review has described 
several protocols for which there are strengths and limitations and consequently demonstrates that reporting of a 
robust methodology to produce confidence in the data generated is paramount.  As the provider of biological 
information, the selection of an appropriate cell line needs careful consideration and results need to be interpreted 
around cellular characteristics and the heterogeneous potential of the population.  The addition of osteogenic factors 
can additionally create super-physiological osteogenic induction, which can mask the true osteoinductive potential of 
the implant surface.  The better in vitro assays aim to map the changing differentiation status of the skeletal stromal 
cells through to a mature osteoblast, where in order to obtain sufficient discrimination in analysis, assays monitor 
several osteogenic markers, acquiring a series of data points over a time course relevant to their temporal expression.  
The research aim for many studies can thus identify whether a surface modification is able to accelerate the 
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osseointegration process.  However, this review has also highlighted how osteoblast differentiation is influences by the 
paracrine signalling from other cells such as macrophages.  Indeed, additional in vitro studies that assess the influence 
of these cells have been demonstrated to provide valuable information that allows better interpretation of subsequent 
in vivo data.   
Ultimately, in vitro analyses do provide important research tools for rapid and relatively inexpensive screening 
of the many different implant surface designs now possible.  They can provide data which provide the scientific 
justification to support selection of those surfaces to be taken through for in vivo assessments.  In this regard, in vitro 
assays contribute to the ethical reduction of animal experimentation, although they cannot fully replace in vivo 
investigations.  However, if reductionist aims are to be successful, it is important that the strengths and limitations of in 
vitro assays should be recognised to provide a critical assessment and prevent the selection of false positive surfaces. 
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Table 1: Comparison of factors for consideration when selecting in vitro or in vivo methodologies. 
 
Factor for consideration In vitro In vivo 
Cost Relatively cheap – Utilises various 
cells, many of which can be culture 
expanded to enhance cost 
effectiveness. 
Expensive – Costs of animal purchase, 
care, housing, etc. in addition to costs 
for post-analysis 
Technical difficulty Technically simple Technically challenging – Requires 
animal handling training, knowledge of 
surgical technique, etc. 
Licensing requirements No licence required Requires ethical licence 
Data acquired and evaluation Usually limited to assessing effects on 
one cell type per assay (unless using 
co-culture system) 
Holistic evaluation based on many cell 
types in a dynamic, living system 
Ethical considerations Limited to source of cells and reagents Multiple ethical considerations 
Technicalities of model systems Absence of bio-kinetics may cause 




Cells can undergo changes throughout 
culture (cell instability) 
Differences in animal species to 
humans may cause results not to be 
extrapolated clinically 
 
Different animal species have different 
bone growth and maturation rates 





Table 2: Advantages and disadvantages of commonly used in vitro cell models.   
Cell type Advantages Disadvantages 
Primary human 
BMSCs 
Relevant for clinical translation 
Safe from malignant transformation 
Limited replicative lifespan in culture 
Phenotypic alterations with prolonged culture 





Ability to study bone matrix deposition and 
mineralisation independently of other cells 
Limited supply 
Long isolation procedure 
Primary rodent 
BMSCs 
High differentiation potential towards 
osteoblasts 
Reduced differentiation capacity throughout 
culturing 
Interspecies phenotypic differences 




Comparable developmental sequence to 
primary human osteoblasts 
More rapid isolation compared to primary 
human osteoblasts 
Variations in differentiation potential between 
species 
Slow proliferation immediately after isolation  




Lack expression of differentiated osteoblasts 
Poor mineralisation potential 
P53 deficient 
SaOS-2 Reproducible synthesis of mineralised matrix 
Temporal expression of mature osteocytic 
genes 
Lack growth contact inhibition (not restricted 
to monolayer growth) 
P53 deficient 
7F2 Indefinite growth potential 
Homogeneous population 
Intermediate differentiation capacity between 
adipocytes and osteoblasts 
MC3T3-E1 High differentiation capacity towards 
osteoblasts 
Undergo sequential steps of differentiation 
Reduced mineralisation capacity throughout 
culturing 
Sub-clone variations 
U2-OS Responsive to BMP-2 
Support outgrowth of haematopoietic 
endothelial cells 
Possess functional p53 tumour suppressor 
gene 
Narrower range of chromosomal aneusomy 
compared to p53 deficient cells 
Aneuploidy 
ROS 17/2.8 Mature osteoblast-like cells, thus more 
reproducible osteogenic response. 
Differential potential limited to late stages 
UMR-106 ALP expression indicative of late stage 
osteoblasts 
Exist as two sub-clones (differentiated by from 
presence of calcitonin receptors) 
MBA-15 Possess in vitro and in vivo osteogenic 
differentiation potential 






Figure 1:  The four continuous and overlapping stages of bone healing.  Each stage involves the activities of different cell populations, responsible for the synthesis of an 
extracellular matrix which acts as a scaffold and reservoir for known growth factors and cytokines.  The signalling activity of these proteins encourages the recruitment of other 
cells, including immune, endothelial and stromal cells which bring about remodelling of the healing tissue and a change in the signalling environment. This allows for the removal 




Figure 2:  The temporal appearance of bone osteogenic markers produced during the culture of skeletally-derived stromal cells.  Dependent upon the starting seeding density, 
cells initially enter a phase of proliferation which then down-regulates before osteoprogenitor cells enter terminal differentiation down the osteoblast lineage.  It is important to 
recognise that some of the osteogenic markers are now known not to span the full range of osteoblast differentiation status.  Dependent upon the cell source used in the assay, 




Figure 3: The role of macrophages in the bone healing process.  During early wound healing the M1 phenotype is proposed to predominate which is pro-inflammatory in nature 
and performs roles in the removal of bacteria, bacterial antigens and particulate matter and ions released from an implant surface.  As bone healing progresses the 
macrophage phenotype changes to the anti-inflammatory M2.  Prolonged presence of M1 has been associated with delayed healing and tissue fibrosis.  Biomaterials that 
promote M2 phenotype have been associated with improved integration due to improved tissue healing.  Figure represents summary of information from published 
reviews88,89. 
